Recently Featured

Novartis to acquire Myricx Bio in up to $1.5bn deal

August 12, 2026
Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5 billion. This acquisition reflects Novartis’ strategic focus on enhancing its pipeline in innovative therapies, particularly in the realm of biologics and advanced therapeutics. The move comes as the pharmaceutical industry continues to see a…

MHRA Approves Retifanlimab (ZYNYZ) for Advanced Merkel Cell Skin Cancer Treatment

August 12, 2026
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Retifanlimab, marketed as ZYNYZ, for the treatment of advanced Merkel cell carcinoma (MCC). This decision marks a significant advancement in the therapeutic options available for a rare and aggressive skin cancer that originates from Merkel cells, which are specialized neuroendocrine cells located…

Besins Healthcare boosts drug delivery portfolio with UniD deal

August 11, 2026
Besins Healthcare has expanded its pharmaceutical operations with the acquisition of UniD Manufacturing, which specialises in long-acting drug delivery technologies. This strategic move enhances Besins’ capabilities in the drug delivery sector, allowing the company to leverage UniD’s innovative technologies and expertise to improve patient outcomes. The integration of UniD into Besins’ portfolio aligns with the…

The FDA’s Opportunity to Regulate the Peptide Market Effectively

August 11, 2026
Americans are increasingly turning to peptide compounds—short chains of amino acids touted for benefits such as recovery, sleep enhancement, performance improvement, metabolic health, and longevity. A significant portion of these compounds is sourced from unregulated online sellers and informal markets, often lacking medical supervision, reliable quality controls, and accurate dosing information. This trend underscores a…

Ongoing Cases